Transcription factor that affects the expression of a large set of genes. Recognizes and binds to the consensus sequence 5'-[CAT]AGG[TC]A-3' in the promoter region. Plays a major role in the repression of a specific subset of hypoxic genes (e.g. ANB1, DAN1 and HEM13) under aerobic conditions. Acts synergistically with the transcription factor ROX1 to recruit the general repression complex SSN6-TUP1 to the promoter of hypoxic genes. Represses transcription of ergosterol biosynthetic genes. Negatively regulates pheromone-induced gene expression. Can act as a transcriptional activator (e.g. of genes like CYC1, SUC2 and the Ty long terminal repeat delta promoter). Induced under aerobic conditions and repressed under anaerobic conditions. The prion domain (PrD) is a Gln/Asn (Q/N)-rich domain, which is unstructured in its native, soluble form, and which forms a parallel in-register beta-sheet in its amyloid form. [MOT3+] is the prion form of MOT3. [MOT3+] is the result of a conformational change of the cellular MOT3 protein that becomes self-propagating and infectious. This conformational change generates a form of MOT3 that assembles into amyloid fibrils. [MOT3+]-aggregates sequester soluble MOT3, resulting in a loss-of-function phenotype for MOT3. [MOT3+] can be cured by GdnHCl and by inactivation of the molecular chaperone HSP104, which is required for [MOT3+] propagation. It is speculated that prion properties of transcription factors may generate an optimized phenotypic heterogeneity that buffers yeast populations against diverse environmental insults. Present with 1690 molecules/cell in log phase SD medium.